🇺🇸 FDA

Intelligence · Patent portfolio

NORTHWEST BIOTHERAPEUTICS Patents

Full USPTO pharma patent portfolio for NORTHWEST BIOTHERAPEUTICS — grant dates, expiration, and drug cross-links.

Patents
595
Expiring ≤24m
13

Quick answer

NORTHWEST BIOTHERAPEUTICS has 595 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 13 expire within 24 months — use filters for patent-cliff planning.

Page 3 of 13

  1. US 11666671

    Spatial mapping of kidney functions

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11666562

    Ilaprazole for inhibiting the release of enveloped viruses from cells

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11666637

    Insulin-loaded metal-organic frameworks

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11666547

    Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1)

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11648211

    Nanoencapsulated combination drug formulations

    Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11633503

    Delivery of oligonucleotide-functionalized nanoparticles

    Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11624125

    Stabilization of colloidal crystals engineered with nucleic acid

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11613754

    Toxic RNAi active seed sequences for killing cancer cells

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11607462

    Systems and methods for minimally-invasive assessment of toxicity-induced tissue injury

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11566224

    Dendritic cell generator

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11566016

    MAP kinase modulators and uses thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11560414

    Kits comprising myokines and platinum-based chemotherapeutic agents for treating colorectal cancer

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11559609

    Bone-promoting thermoresponsive macromolecules

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11559556

    Citrus fruit extract-mediated synthesis of tellurium nanomaterials having biomedical applications

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11554103

    Compositions and methods to reduce pharmaceutical-induced toxicity

    Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11542538

    Method for rapid in vitro synthesis of glycoproteins via recombinant production of n-glycosylated proteins in prokaryotic cell lysates

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11541086

    Compositions and methods for treating Alzheimer's disease

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11535648

    Isolated darobactin A analog compounds and compositions thereof

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11530432

    Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11529417

    Wound healing through sirt1 overexpression

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11518750

    3-methylideneoxan-4-one compounds and substituted derivatives thereof as inhibitors of telomerase

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11517648

    Nanofiber paste for growth factor delivery and bone regeneration

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11510872

    Nanoparticle-lipid composite carriers and uses thereof

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11510916

    Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11497788

    Supramolecular glycosaminoglycans

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11497713

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11491231

    Peptide-oligonucleotide chimeras (POCs) as programmable biomolecular constructs for the assembly of morphologically-tunable soft materials

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11485734

    Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11464719

    Cosmetic and dermatological compositions

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11453640

    Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy

    Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11446271

    Methods and compositions for increasing the potency of antifungal agents

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11439635

    B cell lymphoma 6 protein (BCL6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11439632

    Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11439590

    Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof

    Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11433131

    Adoptive cell therapy using spherical nucleic acids (SNAs)

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11413337

    Peptide conjugated particles for the treatment of inflammation

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11401387

    Photocontrolled dynamic covalent linkers for polymer networks

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11389517

    Peptide conjugated particles

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11371008

    Systems for producing cellular immunotherapeutics and methods of use thereof

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11369622

    Methods and compounds to inhibit enveloped virus release

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11364304

    Crosslinked micellar spherical nucleic acids

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11344569

    Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11311485

    Self-assembled particles for targeted delivery of immunomodulators to treat autoimmunity and cancer

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11304988

    Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (KLC1C)

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11299496

    Ligands for alpha-7 nicotinic acetylcholine receptors and methods of treating neurological and inflammatory conditions

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11298430

    Magnetic nanocomposite compositions

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11285106

    Synthetic nanostructures including nucleic acids and/or other entities

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11246871

    Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does NORTHWEST BIOTHERAPEUTICS have?

595 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do NORTHWEST BIOTHERAPEUTICS patents expire?

13 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.